Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

What this study is about

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

Who can join (things the study team will check)

✅ You may be able to join if…

• Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and not otherwise specified).
• Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment.
• Participants must be able to comprehend English or Spanish (for survey completion).
• Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location.
• Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment.
• Participant must reside in the United States, officially determined per patient report on Self-reported Screening Survey
• In the treating provider's opinion, the participant should have a life expectancy of >=6 months. Participants in hospice are not eligible. Optional Sub-study (available at select sites only):
• Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU).
• Must be receiving treatment at the WF CCC and VCU.
• Must be diagnosed with non-small cell lung cancer.
• Must be planning to receive paclitaxel as part of their chemotherapy in conjunction with Immune Checkpoint Inhibitor (ICIs) PD-1, PD-L1 or CTLA-4.

🚫 You may not be able to join if…

• Currently enrolled in an interventional supportive treatment trial to manage cancer symptoms.
• Participants with known pregnancy.
• Participant received systemic therapy treatment for prior cancer(s) including chemotherapy, immunotherapy, targeted therapy, and hormonal therapy.
• Participants enrolled in hospice. Optional Substudy (available at select sites only):
• Participants with chronic or ongoing steroid or immunomodulatory agents (i.e., prednisone, dexamethasone, etanercept, infliximab, etc.). The use of glucocorticoids as pre-medications for chemotherapy treatment is allowed.
• Participants with a history of HIV, hepatitis B or hepatitis C.

Where this trial is running

• Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
• Kingman Regional Medical Center, Kingman, Arizona, United States
• Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
• Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
• NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
• Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
• Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States
• PCR Oncology, Arroyo Grande, California, United States
• Mercy Cancer Center - Carmichael, Carmichael, California, United States
• Mercy San Juan Medical Center, Carmichael, California, United States
• Kaiser Permanente Dublin, Dublin, California, United States
• Mercy Cancer Center - Elk Grove, Elk Grove, California, United States

+ 455 more sites.

Who to contact

Karen Craver · 336-716-0891 · NCORP@wfusm.edu

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06418204.